Chief Business Officer Gregory Weinhoff sold 11,742 shares of Centessa Pharmaceuticals PLC (CNTA, Financial) on October 25, 2024, according to a recent SEC Filing. Following this transaction, the insider now owns 183,266 shares of the company.
Centessa Pharmaceuticals PLC operates as a biopharmaceutical company focused on discovering and developing impactful medicines for patients. The company's approach combines the strengths of a large-scale pharmaceutical company with the innovation and drive of the biotechnology sector.
Over the past year, Gregory Weinhoff has sold a total of 113,361 shares and has not made any purchases of the company's stock. This recent transaction is part of a broader trend observed within the company, where there have been 12 insider sells and no insider buys over the past year.
Shares of Centessa Pharmaceuticals PLC were trading at $15.38 on the day of the transaction. The company's market cap is approximately $1.99 billion.
The valuation metrics for Centessa Pharmaceuticals PLC include a price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. The company's valuation can also be assessed using the GF Value, which provides a reference point for high-quality investments.
This insider sale might be of interest to investors tracking insider behaviors as an indicator of confidence levels in the company's future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
